Trials / Conditions / Non-small Cell Lung Cancer Recurrent

Non-small Cell Lung Cancer Recurrent

15 registered clinical trials studyying Non-small Cell Lung Cancer Recurrent — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Rec NCT07355205	Washington University School of Medicine	Phase 2
Not Yet Recruiting	Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non- NCT06848426	Jiangxi Provincial People's Hopital	N/A
Recruiting	Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint NCT06463665	Genelux Corporation	Phase 2
Unknown	Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Ca NCT05842018	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Active Not Recruiting	A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors NCT05736731	A2 Biotherapeutics Inc.	Phase 1 / Phase 2
Completed	Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chi NCT05110118	Shandong Boan Biotechnology Co., Ltd	Phase 1
Terminated	ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer NCT03445000	ETOP IBCSG Partners Foundation	Phase 2
Unknown	A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects Wi NCT03533127	Luye Pharma Group Ltd.	Phase 3
Unknown	Cancer Panel From Blood of Lung Cancer Patients NCT03235765	Seoul National University Hospital	—
Terminated	A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer NCT02967133	Alliance Foundation Trials, LLC.	Phase 2
Terminated	Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer NCT02460367	NewLink Genetics Corporation	Phase 1
Completed	A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in R NCT02423343	Eli Lilly and Company	Phase 1 / Phase 2
Terminated	Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer NCT01774578	NewLink Genetics Corporation	Phase 2 / Phase 3
Terminated	Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung NCT01471964	Fox Chase Cancer Center	Phase 1 / Phase 2
Completed	A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotini NCT01523340	Chonnam National University Hospital	—